N-(3-CyanoproPyl)-1,3,3,5.5-pentamethylcyclohexylamine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-(3-CyanoproPyl)-1,3,3,5.5-pentamethylcyclohexylamine
• 英文别名: N-(3-Cyanopropyl)-1,3,3,5,5-pentamethylcyclohexylamine；4-[(1,3,3,5,5-pentamethylcyclohexyl)amino]butanenitrile
• 化学式: C₁₅H₂₈N₂
• 分子量: 236.401
• InChiKey: PYVXAOLCMAAFGR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  35.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(3-CyanoproPyl)-1,3,3,5.5-pentamethylcyclohexylamine 在 palladium-carbon 盐酸 作用下， 以 乙醇 为溶剂， 生成 MRZ 2/705
  参考文献：
  名称：

  1-Amino-alkylcyclohexane NMDA receptor antagonists

  摘要：

  某些1-氨基烷基环己烷类化合物是系统活性的非竞争性NMDA受体拮抗剂，具有快速的阻滞/解除动力学和强烈的电压依赖性，因此在缓解由谷氨酸能传递干扰引起的情况方面具有广泛的实用价值，包括在治疗涉及相同疾病的中枢神经系统疾病中以及非NMDA适应症中，由于它们的免疫调节、抗疟疾、抗伯纳病毒和抗丙型肝炎活性和实用性。其中药物组合物和一种治疗条件的方法，该条件通过使用NMDA受体拮抗剂得到缓解，以及前述的非NMDA适应症和涉及的1-氨基烷基环己烷活性化合物的制备方法。

  公开号：

  US06034134A1
• 作为产物：
  描述：

  neramexane hydrochloride 、 4-溴丁腈 在 sodium carbonate 作用下， 以 四氢呋喃 为溶剂， 反应 85.0h， 以86%的产率得到N-(3-CyanoproPyl)-1,3,3,5.5-pentamethylcyclohexylamine
  参考文献：
  名称：

  1-CYCLIC AMINO-ALKYLCYCLOHEXANE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE AS ANTICONVULSANTS

  摘要：

  公开号：

  EP1228052B1

文献信息

• 1-Amino-alkylcyclohexane NMDA receptor antagonists
  申请人：Merz + Co. GmbH & Co.

  公开号：US06034134A1

  公开（公告）日：2000-03-07

  Certain 1-aminoalkylcyclohexanes are systemically-active uncompetitive NMDA receptor antagonists having rapid blocking/unblocking kinetics and strong voltage-dependency and are therefore useful in the alleviation of conditions resulting from disturbances of glutamatergic transmission giving them a wide range of utility in the treatment of CNS disorders involving the same, as well as in non-NMDA indications, due to their immunomodulatory, antimalarial, anti-Borna virus, and anti-Hepatitis C activities and utilities. Pharmaceutical compositions thereof and a method-of-treating conditions which are alleviated by the employment of an NMDA receptor antagonist, as well as the aforementioned non-NMDA indications, and a method for the preparation of the active 1-aminoalkylcyclohexane compounds involved.

  某些1-氨基烷基环己烷是系统性活性的非竞争性NMDA受体拮抗剂，具有快速的阻滞/解除动力学和强烈的电压依赖性，因此在缓解由谷氨酸能传递干扰引起的病症方面具有广泛的用途，包括在涉及相同情况的中枢神经系统疾病的治疗中，以及在非NMDA适应症中，由于它们的免疫调节，抗疟疾，抗Borna病毒和抗丙型肝炎活性和用途。其中的制药组合物和治疗使用NMDA受体拮抗剂缓解的病症的方法，以及前述的非NMDA适应症和涉及的活性1-氨基烷基环己烷化合物的制备方法。
• 1-amino-alkylcyclohexane NMDA receptor antagonists
  申请人：Merz + Co. GmbH & Co.

  公开号：US06071966A1

  公开（公告）日：2000-06-06

  Certain 1-aminoalkylcyclohexanes are systemically-active uncompetitive NMDA receptor antagonists having rapid blocking/unblocking kinetics and strong voltage-dependency and are therefore useful in the alleviation of conditions resulting from disturbances of glutamatergic transmission giving them a wide range of utility in the treatment of CNS disorders involving the same, as well as in non-NMDA indications, due to their immunomodulatory, antimalarial, anti-Borna virus, and anti-Hepatitis C activities and utilities. Pharmaceutical compositions thereof and a method-of-treating conditions which are alleviated by the employment of an NMDA receptor antagonist, as well as the aforementioned non-NMDA indications, and a method for the preparation of the active 1-aminoalkylcyclohexane compounds involved.

  某些1-氨基烷基环己烷是系统活性的非竞争性NMDA受体拮抗剂，具有快速的阻断/解除阻断动力学和强烈的电压依赖性，因此在缓解由谷氨酸能传递干扰引起的病症方面具有广泛的应用价值，同时也具有免疫调节、抗疟疾、抗波纳病毒和抗丙型肝炎活性和用途，因此在治疗涉及相同疾病的中枢神经系统疾病以及非NMDA适应症方面具有广泛的用途。其中的制药组合物和治疗使用NMDA受体拮抗剂缓解的病症的方法，以及前述的非NMDA适应症和涉及的活性1-氨基烷基环己烷化合物的制备方法。
• US6034134A
  申请人：——

  公开号：US6034134A

  公开（公告）日：2000-03-07
• US6071966A
  申请人：——

  公开号：US6071966A

  公开（公告）日：2000-06-06
• [EN] 1-CYCLIC AMINO-ALKYLCYCLOHEXANE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE AS ANTICONVULSANTS<br/>[FR] COMPOSES AMINO-ALKYLCYCLOHEXANE 1-CYCLIQUES, LEURS COMPOSITIONS PHARMACEUTIQUES, ET LEUR UTILISATION COMME ANTICONVULSIVANTS
  申请人：MERZ & CO GMBH & CO

  公开号：WO2001032640A1

  公开（公告）日：2001-05-10

  Certain 1-cyclic amino-alkylcyclohexanes selected from the group consisting of those of formula (I) wherein R* is -(CH2)n-(CR6R7)m-NR8R9; wherein n+m=0,1, or 2; wherein R1 through R7 are independently selected from the group consisting of hydrogen and lower-alkyl (1-6c), at least R?1, R4, and R5¿ being lower-alkyl, and wherein R?8 and R9¿ together represent lower-alkylene -(CH¿2?)x- wherein x is 2 to 5, inclusive, and enantiomers, optical isomers, hydrates, and pharmaceutically acceptable salts thereof, are systemically active uncompetitive NMDA receptor antagonists and are therefore useful in the alleviation of conditions resulting from disturbances of glutamatergic transmission. More importantly, these compounds exhibit outstanding anticonvulsant and anti-seizure activity which is not shared by closely-related noncyclic amino compounds. Pharmaceutical compositions thereof and a method-of-treating conditions which are alleviated by the employment of the same, especially the alleviation of convulsions and seizures, and method for the preparation of the active 1-cyclic amino-alkylcyclohexane compounds involved and the manufacture of medicaments therefrom.